Smartleaf Asset Management’s Taysha Gene Therapies TSHA Stock Holding History

Smartleaf Asset Management’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.24K	Buy	+449	New	+$2.59K	﹤0.01%	3006

Other funds holding TSHA

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Smartleaf Asset Management's TSHA Position: Q3 2026 in Review

Smartleaf Asset Management opened a new position in Taysha Gene Therapies (TSHA) in Q3 2026: 449 shares worth $2.24K. The stake represents ﹤0.01% of the portfolio and ranks #3006 among its holdings.

135 funds tracked by Wall St. Rank hold TSHA as of Q3 2026.

Smartleaf Asset Management held 449 shares of Taysha Gene Therapies worth $2.24K as of Q3 2026.
Taysha Gene Therapies was a new Smartleaf Asset Management position in Q3 2026.
Taysha Gene Therapies made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q3 2026, its #3006 holding.
135 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2026.

Based on Smartleaf Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.